Literature DB >> 31168836

Efficacy and safety of a bortezomib and reduced-intensity cytarabine-based protocol, TMC ALLR1, for relapsed childhood ALL in India.

Prakriti Roy1, Rubina Islam1, Debparna Saha1, Manash Gogoi1, Deepak Kumar Mishra2, Neeraj Arora2, Mayur Parihar2, Shekhar Krishnan1,3, Vaskar Saha1,3.   

Abstract

The feasibility of bortezomib (BZB) in induction and reduced cytarabine doses in intensification was evaluated in children with relapsed acute lymphoblastic leukaemia (rALL) at a single centre in India. Of 55 children with rALL, 23 received supportive care and 7 refused treatment, with a median survival of 2 (interquartile range 1-6) months. Twenty-two (88%) of 25 children who were treated achieved second remission and 9 (69%) of 13 had end-of-induction minimal residual disease of <10-4 . The lower cytarabine dose was associated with decreased hospitalisation. One-year event-free and overall survival for the treated group was 74·7% (95% confidence interval 52-88) and 79·6% (58-91) respectively.
© 2019 British Society for Haematology and John Wiley & Sons Ltd.

Entities:  

Keywords:  bortezomib; limited resources; reduced-intensity cytarabine; relapsed acute lymphoblastic leukaemia

Mesh：

Substances：

Year:  2019        PMID： 31168836      PMCID： PMC6785345          DOI： 10.1111/bjh.16005

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


  14 in total

1.  Evaluation of new markers for minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia: CD73 and CD86 are the most relevant new markers to increase the efficacy of MRD 2016; 00B: 000-000.

Authors:  Prashant R Tembhare; Sitaram Ghogale; Nisha Ghatwai; Yajamanam Badrinath; Nikesh Kunder; Nikhil V Patkar; Asma R Bibi; Gaurav Chatterjee; Brijesh Arora; Gaurav Narula; Shripad Banawali; Nilesh Deshpande; Prathibha Amare; Sumeet Gujral; Papagudi G Subramanian
Journal:  Cytometry B Clin Cytom       Date:  2016-10-27       Impact factor: 3.058

2.  FxCycle™ Based Ploidy Correlates with Cytogenetic Ploidy in B-Cell Acute Lymphoblastic Leukemia and Is Able to Detect the Aneuploid Minimal Residual Disease Clone.

Authors:  Nishit Gupta; Mayur Parihar; Sambhunath Banerjee; Subhajit Brahma; Ravikiran Pawar; Asish Rath; Sundar Shewale; Manish Singh; Arun Sasikumaran Nair Remani; Shekhar Krishnan; Arpita Bhatacharyya; Anirban Das; Jeevan Kumar; Saurabh Bhave; Vivek Radhakrishnan; Reena Nair; Mammen Chandy; Deepak Mishra; Neeraj Arora
Journal:  Cytometry B Clin Cytom       Date:  2019-02-04       Impact factor: 3.058

3.  Isolated testicular relapse in acute lymphoblastic leukemia - effective treatment with the modified CCG-112 protocol.

Authors:  Goyal Shama; Roshni Bhagwat; Suresh K Pai; Purna A Kurkure; Chandrika N Nair; Purvish M Parikh; Maryann A Mukaden; Shripad D Banavali
Journal:  Indian J Cancer       Date:  2005 Apr-Jun       Impact factor: 1.224

4.  An effective modestly intensive re-induction regimen with bortezomib in relapsed or refractory paediatric acute lymphoblastic leukaemia.

Authors:  Gertjan J L Kaspers; Denise Niewerth; Bram A J Wilhelm; Peggy Scholte-van Houtem; Marta Lopez-Yurda; Johannes Berkhof; Jacqueline Cloos; Valerie de Haas; Ron A Mathôt; Andishe Attarbaschi; André Baruchel; Eveline S de Bont; Franca Fagioli; Claudia Rössig; Thomas Klingebiel; Barbara De Moerloose; Brigitte Nelken; Giuseppe Palumbo; Dirk Reinhardt; Pierre-Simon Rohrlich; Pauline Simon; Arend von Stackelberg; Christian Michel Zwaan
Journal:  Br J Haematol       Date:  2018-04-20       Impact factor: 6.998

5.  The combination of bortezomib with chemotherapy to treat relapsed/refractory acute lymphoblastic leukaemia of childhood.

Authors:  Alice Bertaina; Luciana Vinti; Luisa Strocchio; Stefania Gaspari; Roberta Caruso; Mattia Algeri; Valentina Coletti; Carmelo Gurnari; Mariateresa Romano; Maria Giuseppina Cefalo; Katia Girardi; Valentina Trevisan; Valentina Bertaina; Pietro Merli; Franco Locatelli
Journal:  Br J Haematol       Date:  2017-01-24       Impact factor: 6.998

6.  Bortezomib reinduction chemotherapy in high-risk ALL in first relapse: a report from the Children's Oncology Group.

Authors:  Terzah M Horton; James A Whitlock; Xiaomin Lu; Maureen M O'Brien; Michael J Borowitz; Meenakshi Devidas; Elizabeth A Raetz; Patrick A Brown; William L Carroll; Stephen P Hunger
Journal:  Br J Haematol       Date:  2019-04-07       Impact factor: 6.998

7.  Efficacy and safety of once-weekly bortezomib in multiple myeloma patients.

Authors:  Sara Bringhen; Alessandra Larocca; Davide Rossi; Maide Cavalli; Mariella Genuardi; Roberto Ria; Silvia Gentili; Francesca Patriarca; Chiara Nozzoli; Anna Levi; Tommasina Guglielmelli; Giulia Benevolo; Vincenzo Callea; Vincenzo Rizzo; Clotilde Cangialosi; Pellegrino Musto; Luca De Rosa; Anna Marina Liberati; Mariella Grasso; Antonietta P Falcone; Andrea Evangelista; Michele Cavo; Gianluca Gaidano; Mario Boccadoro; Antonio Palumbo
Journal:  Blood       Date:  2010-08-31       Impact factor: 22.113

8.  Investigation of the freely available easy-to-use software 'EZR' for medical statistics.

Authors:  Y Kanda
Journal:  Bone Marrow Transplant       Date:  2012-12-03       Impact factor: 5.483

9.  Determinants of Treatment Abandonment in Childhood Cancer: Results from a Global Survey.

Authors:  Paola Friedrich; Catherine G Lam; Geetinder Kaur; Elena Itriago; Raul C Ribeiro; Ramandeep S Arora
Journal:  PLoS One       Date:  2016-10-13       Impact factor: 3.240

10.  Outcomes of patients with childhood B-cell precursor acute lymphoblastic leukaemia with late bone marrow relapses: long-term follow-up of the ALLR3 open-label randomised trial.

Authors:  Catriona Parker; Shekhar Krishnan; Lina Hamadeh; Julie A E Irving; Roland P Kuiper; Tamas Révész; Peter Hoogerbrugge; Jeremy Hancock; Rosemary Sutton; Anthony V Moorman; Vaskar Saha
Journal:  Lancet Haematol       Date:  2019-02-27       Impact factor: 30.153
View more
  1 in total

Review 1.  The Role of Proteasome Inhibitors in Treating Acute Lymphoblastic Leukaemia.

Authors:  Chun-Fung Sin; Pui-Hei Marcus Man
Journal:  Front Oncol       Date:  2021-12-23       Impact factor: 6.244
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.